Product Center
Trivalent Influenza Virus Subunit Vaccine (Adjuvanted)
We are also developing an investigational trivalent influenza virus subunit vaccine (adjuvanted). Its mechanism of action, formulation process and manufacturing technology are similar to those of the investigational quadrivalent influenza virus subunit vaccine (adjuvanted), with the only difference being that one influenza B virus subtype (Yamagata) is omitted during the formulation process. We obtained the Investigational New Drug (IND) approval for the investigational trivalent influenza virus subunit vaccine (adjuvanted) in October 2024, and it is expected to initiate Phase I clinical trials in the fourth quarter of 2025.
For all the above-mentioned products, we are seeking localized cooperation, technology transfer, and agency partnerships in overseas markets.
- Rrecommend Products
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
